ArticleNeuro-oncology advances2023
The joint impacts of sex and race/ethnicity on incidence of grade 1 versus grades 2-3 meningioma across the lifespan.
Article in Neuro-oncology advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 17 citations in OpenAlex.
- A proteogenomic RNA processing mechanism drives sex differences in meningioma.Research square · 2026Article
- The effect of sex on vestibular schwannoma incidence varies across the lifespan and modifies associations with race/ethnicity.Journal of neuro-oncology · 2026Article
- Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users.Journal of neuro-oncology · 2026Article
- Subsequent Meningiomas Among Survivors of Childhood Cancer.JAMA network open · 2025Article
- Evolving Treatment Paradigms of Meningiomas; a Precision Medicine Perspective.Current neurology and neuroscience reports · 2025Review
- The effect of sex on vestibular schwannoma incidence varies across the lifespan and modifies associations with race/ethnicity.Research square · 2025Article
- A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Causal assessments of multilevel social determinant factors on meningioma disparities in the United States.Neuro-oncology practice · 2025Article
- Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Precision preclinical modeling to advance cancer treatment.Journal of the National Cancer Institute · 2025Review
- Meningioma: Novel Diagnostic and Therapeutic Approaches.Biomedicines · 2025Review
- Malignant Meningiomas: From Diagnostics to Treatment.Diagnostics (Basel, Switzerland) · 2025Review
- Grade-stratified meningioma risk among individuals who are non-Hispanic Black and interactions with male sex.Journal of the National Cancer Institute · 2025Article
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- Article
- Association of county-level socioeconomic status with meningioma incidence and outcomes.Neuro-oncology · 2024Article
- The dichotomy of central nervous system cancer burden: A global analysis revealing diagnosis-driven epidemics and therapy-resistant mortality.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous research has identified older age, African-American race, and female sex as meningioma risk factors, but there is limited information on their joint effects, or on how these demographic factors vary across strata of tumor grade. Methods: The Central Brain Tumor Registry of the United States (CBTRUS) is a population-based registry combining data from the CDC's National Program of Cancer Registries and NCI's Surveillance, Epidemiology and End Results Program which covers ~100% of the U.S. population and aggregates incidence data on all primary malignant and nonmalignant brain tumors. These data were used to explore the joint impacts of sex and race/ethnicity on average annual age-adjusted incidence rates of meningioma. We calculated meningioma incidence rate ratios (IRRs) by sex and race/ethnicity, across strata of age and tumor grade. Results: Compared to individuals who are non-Hispanic White, individuals who are non-Hispanic Black had significantly higher risk of grade 1 (IRR = 1.23; 95% CI: 1.21-1.24) and grade 2-3 meningioma (IRR = 1.42; 95% CI: 1.37-1.47). The female-to-male IRR peaked in the fifth decade of life across all racial/ethnic groups and tumor grades, but was 3.59 (95% CI: 3.51-3.67) for WHO grade 1 meningioma and 1.74 (95% CI: 1.63-1.87) for WHO grade 2-3 meningioma. Conclusions: This study reveals the joint effects of sex and race/ethnicity on meningioma incidence throughout the lifespan and across strata of tumor grade, highlighting incidence disparities among females and African-Americans that may inform future strategies for tumor interception.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.